Forefront Wealth Partners LLC Takes Position in Astera Labs, Inc. $ALAB

Forefront Wealth Partners LLC bought a new position in Astera Labs, Inc. (NASDAQ:ALAB) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 4,739 shares of the company’s stock, valued at approximately $928,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ALAB. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Astera Labs in the 2nd quarter worth approximately $29,000. Bernard Wealth Management Corp. bought a new stake in Astera Labs in the second quarter worth $36,000. Clearstead Trust LLC lifted its stake in Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. boosted its position in Astera Labs by 68.6% during the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after buying an additional 194 shares during the period. Finally, Manchester Capital Management LLC grew its stake in shares of Astera Labs by 141.5% during the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after buying an additional 283 shares during the last quarter. 60.47% of the stock is currently owned by institutional investors.

Astera Labs Stock Up 0.4%

NASDAQ:ALAB opened at $170.84 on Wednesday. The firm’s fifty day simple moving average is $160.32 and its 200 day simple moving average is $159.75. The stock has a market cap of $28.85 billion, a P/E ratio of 153.91, a price-to-earnings-growth ratio of 3.17 and a beta of 1.51. Astera Labs, Inc. has a twelve month low of $47.13 and a twelve month high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.39 by $0.10. The business had revenue of $230.58 million during the quarter, compared to analyst estimates of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company’s revenue for the quarter was up 103.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. On average, analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALAB has been the subject of a number of recent research reports. Citigroup reissued an “outperform” rating on shares of Astera Labs in a research note on Tuesday, December 9th. BNP Paribas assumed coverage on Astera Labs in a research note on Thursday, November 20th. They set an “outperform” rating for the company. BNP Paribas Exane initiated coverage on shares of Astera Labs in a report on Thursday, November 20th. They issued an “outperform” rating and a $225.00 target price on the stock. Barclays reiterated an “equal weight” rating and set a $155.00 price target on shares of Astera Labs in a report on Monday, October 20th. Finally, Bank of America began coverage on shares of Astera Labs in a report on Friday, October 3rd. They issued a “neutral” rating and a $230.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Insider Buying and Selling

In other news, Director Manuel Alba sold 150,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $166.18, for a total value of $24,927,000.00. Following the completion of the transaction, the director owned 1,574,498 shares of the company’s stock, valued at approximately $261,650,077.64. This represents a 8.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Philip Mazzara sold 4,620 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $668,467.80. Following the completion of the transaction, the general counsel owned 147,040 shares of the company’s stock, valued at approximately $21,275,217.60. The trade was a 3.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 576,936 shares of company stock valued at $87,409,540 over the last quarter. 12.50% of the stock is currently owned by insiders.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.